外周T细胞淋巴瘤/自然型鼻型是一种罕见和侵袭性的淋巴瘤，历史上预后不良。我们在这里报告了一个回顾性多中心研究的结果，评估了MGAD（甲氨蝶呤、吉西他滨、L-天冬氨酸酶和地塞米松）方案（二个疗程）与“三明治”放疗联合治疗35名局部新诊断的外周T细胞淋巴瘤/自然型鼻型患者的疗效。32名患者（91%）达到完全缓解。长达59.6个月的中位随访期，2年和5年的无进展生存率和总生存率分别为71%、80%和53%、73%。约有三分之一的患者在中位随访时间为14.5个月内出现复发。副作用可以通过50%、24%和21%的病例分别出现3-4级细胞减少、口腔炎和感染来控制。对13名患者进行天冬氨酸酶活性的监测，结果显示有7名（54%）患者药物失活。我们的结果表明，MGAD化学放疗三明治短期治疗是一种耐受且有效的局部新诊断外周T细胞淋巴瘤患者的治疗选择。© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Extranodal NK/T-cell lymphoma, nasal type is a rare and aggressive form of lymphoma, historically associated with poor prognosis. We report here the results of a retrospective multi-centre study evaluating the efficacy of MGAD (methotrexate, gemcitabine, L-asparaginase and dexamethasone) regimen (two cycles) combined with 'sandwich' radiotherapy in 35 patients with localised newly diagnosed extranodal NK/T-cell lymphoma. Thirty-two patients (91%) reached complete remission. With a long median follow-up of 59.6 months, progression-free and overall survival at 2 and 5 years were 71%, 80% and 53%, 73%, respectively. Around one third of the patients experienced relapse within a median time of 14.5 months. Side-effects were manageable with grades 3-4 cytopenias, mucositis and infection in 50%, 24% and 21% of the cases, respectively. Monitoring of asparaginase activity was performed in 13 patients and showed inactivation of the drug in seven (54%) patients. Our results indicate that a short therapy by sandwich MGAD chemoradiotherapy is a tolerable and effective treatment option in localised newly diagnosed extranodal NK/T-cell lymphoma patients.© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.